Cargando…

Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison

OBJECTIVE: To compare the safety and efficacy of the dipeptidylpeptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes and inadequate glycemic control. DESIGN: Systematic review of randomized controlled trials (RCTs), health economic evaluation studies, systematic reviews, and meta-analyses,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Craddy, Paul, Palin, Hannah-Jayne, Johnson, K. Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/ https://www.ncbi.nlm.nih.gov/pubmed/24664619 http://dx.doi.org/10.1007/s13300-014-0061-3

Ejemplares similares

Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China
por: Lin, Wen-Qiang, et al.
Publicado: (2021)

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
por: Aroor, Annayya R., et al.
Publicado: (2018)

Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors
por: Ray, Chin-Ying, et al.
Publicado: (2021)

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
por: Zimdahl, Heike, et al.
Publicado: (2014)

Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy Volunteers
por: Choi, Hee Youn, et al.
Publicado: (2014)

Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells
por: Wang, Chen, et al.
Publicado: (2023)

Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity
por: Posadas-Sánchez, Rosalinda, et al.
Publicado: (2021)

Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
por: Broxmeyer, Hal E.
Publicado: (2013)

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections
por: Schlicht, Kristina, et al.
Publicado: (2020)

Alopecia areata universalis nach Sitagliptin-Einnahme: Mögliche immunologische Wirkung von Dipeptidylpeptidase-4-Inhibitoren?
por: Kohlmann, Johannes, et al.
Publicado: (2020)

Activity Staining and Inhibition Characterization of Dipeptidylpeptidase-III Enzyme from Goat Brain
por: Attri, Pooja, et al.
Publicado: (2011)

High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes
por: Sinagra, Tiziana, et al.
Publicado: (2015)

Correction: Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections
por: Schlicht, Kristina, et al.
Publicado: (2021)

Manipulation of dipeptidylpeptidase 10 in mouse and human in vivo and in vitro models indicates a protective role in asthma
por: Zhang, Youming, et al.
Publicado: (2018)

High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation
por: Farag, Sherif S., et al.
Publicado: (2017)

Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours
por: Dohi, Osamu, et al.
Publicado: (2009)

Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV
por: Onoyama, Haruna, et al.
Publicado: (2016)

Dipeptidylpeptidase-IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats
por: Tarantola, E., et al.
Publicado: (2012)

Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease
por: Brandes, Juliane, et al.
Publicado: (2022)

Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia
por: Bauvois, B, et al.
Publicado: (1999)

PNS173 Impact of COVID-19 on HTA Bodies and Pharmaceutical Company Pricing and Market Access Activities
por: Thomas, M., et al.
Publicado: (2020)

Dipeptidylpeptidase-IV Activity and Expression Reveal Decreased Damage to the Intrahepatic Biliary Tree in Fatty Livers Submitted to Subnormothermic Machine-Perfusion Respect to Conventional Cold Storage
por: Tarantola, E., et al.
Publicado: (2014)

Post-transcriptional control of nuclear-encoded cytochrome oxidase subunits in Trypanosoma brucei: evidence for genome-wide conservation of life-cycle stage-specific regulatory elements
por: Mayho, Matthew, et al.
Publicado: (2006)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)
por: Kim, Ji-Hea, et al.
Publicado: (2023)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
por: Cha, Seon-Ah, et al.
Publicado: (2017)

Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers
por: Dumville, J. C., et al.
Publicado: (2012)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Wang, Qixian, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
por: Mak, Woh Yon, et al.
Publicado: (2020)

Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Kay, Stephen, et al.
Publicado: (2017)

Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Bae, Jae Hyun, et al.
Publicado: (2021)

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
por: Orme, Michelle, et al.
Publicado: (2014)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes
por: Smith-Palmer, Jayne, et al.
Publicado: (2016)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
por: Min, Se Hee, et al.
Publicado: (2018)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_753hpb50ncjg7spuasmf4ds4ga